查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2011521

心臟衰竭治疗市场：2026-2032年全球市场预测（按药物类别、心臟衰竭类型、给药途径、最终用户和分销管道划分）

Heart Failure Therapeutics Market by Drug Class, Heart Failure Type, Mode Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，心臟衰竭治疗市场价值将达到 291 亿美元，到 2026 年将成长至 316.9 亿美元，到 2032 年将达到 602.3 亿美元，复合年增长率为 10.94%。

主要市场统计数据
基准年 2025 291亿美元
预计年份：2026年 316.9亿美元
预测年份 2032 602.3亿美元
复合年增长率 (%) 10.94%

对现代心臟衰竭药物进行简明背景概述，重点在于临床重点、护理路径以及相关人员的操作决策因素。

心臟衰竭的治疗正处于临床紧迫性、不断发展的分子科学和不断变化的医疗服务模式的交汇点。本执行摘要整合了当前临床医生、保险公司、行业领导者和政策制定者所面临的情况，重点关注影响患者预后的最关键治疗分类和治疗路径。引言部分将近期治疗进展置于不断更新的临床指南和日益增长的慢性病管理关注度的背景下，使后续分析围绕实际应用而非抽象预测。

对药物创新、精细表型分析和不断发展的医疗保健服务模式如何共同重塑治疗策略和获取途径进行详细分析。

心臟衰竭的治疗格局正在经历一场变革，其驱动力包括创新、不断更新的指南以及医疗服务体系的重塑。药理学的进步拓展了临床医生的治疗手段，使其不再局限于传统的血流动力学疗法，而是涵盖了针对代谢、发炎以及肾臟和心臟轴的药物。因此，诸如ACE抑制剂、ARB、 β阻断剂、利尿剂、盐皮质激素受体拮抗剂（MRA）和SGLT2抑制剂等传统药物类别正在被重新评估，并纳入更精细的治疗方案中，而联合用药策略和给药顺序的重要性也日益凸显。

对近期关税趋势对供应链的影响及其对采购、分销和医疗保健系统运营的影响进行全面评估。

美国近期关税政策的变化对心臟衰竭药物产业的製造商、经销商和下游医疗服务提供者产生了多方面的影响。关税的变化会影响整个供应链的成本结构，包括原料药、成品以及用于监测和给药的医疗设备相关产品的到货成本。这些压力可能导致与医院系统和药房网络的合约关係发生变化，进而促使公共和私人支付方重新评估其筹资策略。

透过利用整合药物类别、表型差异、给药途径、医疗保健环境和流通结构的多维细分见解，我们支持有针对性的策略制定。

药物细分提供了必要的分析框架，可以将细微的治疗差异转化为可操作的策略。按药物类别划分，治疗方法选择差异显着。 ACE抑制剂和ARB类药物仍是神经激素调节的基础； β阻断剂抑制交感神经过度活跃；利尿剂用于管理有症状患者的体液平衡；盐皮质激素受体拮抗剂（MRA）有助于拮抗剂抑制盐皮质激素；SGLT2抑制剂则具有超越传统类别界限的有益代谢和肾臟/心臟效应。这些类别层面的差异直接影响临床路径和商业性定位。

区域趋势和医疗保健系统特征决定了世界各地市场在治疗方法引入、报销途径和医疗保健服务方面的差异。

区域趋势对全球心臟衰竭治疗领域的治疗方法采纳、报销和实施方式有着深远的影响。在美洲，支付方结构、整合的医疗网络以及高密度的专科医疗中心促进了通讯协定的快速推广，并为专科通路和医院主导的治疗启动铺平了道路。私人和公共支付方模式的多样性也影响报销谈判和处方药清单，并对治疗价值的体现方式产生连锁反应。

为整合科学差异化、证据产生和经销伙伴以支持治疗方法。

企业策略日益取决于其如何有效地将科学差异化与贯穿整个医疗服务链的实际应用相结合。主要企业和商业机构正将研发、证据产生和生命週期管理重点放在能够满足射血分数正常和降低患者群体未满足医疗需求的化合物和联合治疗上。策略重点包括：在硬终点上证明疗效、阐明合併症患者群体的安全性特征，以及产生可操作的证据以支持在常规临床实践中推广应用。

开发人员、付款方和医疗保健提供者可以采取哪些行动来增强临床和商业途径中的可及性、证据完整性和供应韧性。

行业领导者可以采取切实措施，提高心臟衰竭治疗的可近性、临床疗效和商业性韧性。首先，应使临床开发和核准后证据项目与支付方和医疗保健系统关注的可操作终点（例如避免住院和功能状态）保持一致，同时确保试验能够涵盖与保守治疗和低射血分数组相关的各种患者表型。其次，应制定能够衔接住院和门诊环境的上市和商业化计划，并与医院药房团队、诊所网络和居家照护机构合作，制定清晰的治疗启动和过渡通讯协定。

透过采用稳健的混合方法研究设计，结合临床医生的回馈、有针对性的文献整合和情境分析，我们确保了可操作性和有效性的研究结果。

本研究采用混合方法，旨在产生严谨且可操作的见解，以弥合临床细微差别与商业性现实之间的差距。主要定性资料包括对医院系统、诊所和居家照护机构的活跃循环系统、心臟衰竭专科护理师、药房主任和采购经理进行的结构化访谈，以收集第一线观点对治疗方法选择、实施流程和用药依从性挑战的看法。这些一线见解辅以基于同行评审的临床文献、监管指南和公开的医疗保健系统报告的二手研究，从而将临床疗效、安全性和指南演变置于更广阔的背景中进行分析。

对临床、营运和区域主题进行综合分析，为将治疗进展转化为可持续的患者获益提供切实可行的途径。

总之，目前心臟衰竭的治疗现况呈现显着的临床进展和操作复杂性。治疗方案的差异化已不再局限于传统的血流动力学目标，而是扩展到包括那些能够改善肾功能和代谢的药物，这就需要更加精细的临床决策过程，该过程需综合考虑表型、疾病严重程度和合併症。这些科学进步与医疗服务模式的变革交织，诊所、医院和居家照护在治疗启动、剂量调整和长期管理中各自扮演着不同的角色。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章心臟衰竭治疗市场：依药物类别划分

  • ACE抑制剂
  • ARB
  • β阻断剂
  • 利尿剂
  • MRA
  • SGLT2抑制剂

第九章：以心臟衰竭类型分類的心臟衰竭治疗市场

  • 正常射血分数
    • 急性
    • 慢性的
  • 射血分数降低型
    • 急性
    • 慢性的

第十章：依给药途径分類的心臟衰竭治疗市场

  • 静脉注射
  • 口服

第十一章心臟衰竭治疗市场：依最终用户划分

  • 诊所
  • 居家照护设施
  • 医院

第十二章心臟衰竭药物市场：依分销管道划分

  • 离线
    • 医院药房
    • 零售药房
  • 在线的

第十三章心臟衰竭治疗市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章心臟衰竭治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章心臟衰竭治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国心臟衰竭药物市场

第十七章：中国心臟衰竭药物市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Abiomed, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Boston Scientific Corporation
  • Bristol-Myers Squibb Company
  • Cytokinetics, Inc.
  • Edwards Lifesciences Corporation
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Les Laboratoires Servier
  • Medtronic plc
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-430D42AA0D2E

The Heart Failure Therapeutics Market was valued at USD 29.10 billion in 2025 and is projected to grow to USD 31.69 billion in 2026, with a CAGR of 10.94%, reaching USD 60.23 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 29.10 billion
Estimated Year [2026] USD 31.69 billion
Forecast Year [2032] USD 60.23 billion
CAGR (%) 10.94%

Concise contextual framing of contemporary heart failure therapeutics highlighting clinical priorities, care pathways, and operational decision levers for stakeholders

Heart failure therapeutics occupy a pivotal intersection of clinical urgency, evolving molecular science, and shifting care delivery models. This executive summary synthesizes the contemporary landscape for clinicians, payers, industry leaders, and policy makers, emphasizing the therapeutic classes and care pathways that matter most in shaping patient outcomes. The introduction situates recent therapeutic advances against a backdrop of changing clinical guidelines and heightened attention to chronic disease management, framing the rest of the analysis around practical implications rather than abstract projections.

The discussion foregrounds how incremental innovations across established drug classes, alongside newer agents and adjunctive care strategies, are redefining treatment algorithms. It emphasizes the practical considerations that influence adoption in routine care, such as route of administration, acute versus chronic management distinctions, and where care is delivered-clinic, hospital, or home settings. By anchoring the narrative to real-world decision levers, this section prepares the reader for deeper analysis of landscape shifts, tariff impacts, segmentation insights, and regional dynamics that follow.

Throughout, the tone balances clinical nuance and commercial pragmatism. The introduction does not seek to catalog every development but rather to clarify the themes that determine therapeutic value, stakeholder priorities, and the operational adjustments organizations will need to make to capitalize on emerging opportunities in heart failure care.

Detailed analysis of how pharmacologic innovation, refined phenotyping, and evolving care delivery models are jointly reshaping therapeutic strategies and access pathways

The therapeutic landscape for heart failure is undergoing transformative shifts driven by a confluence of innovation, guideline evolution, and care delivery redesign. Advances in pharmacology are broadening the clinician's toolkit beyond traditional modulators of hemodynamics to include agents that target metabolic, inflammatory, and renal-cardiac axes. As a result, established categories such as ACE inhibitors, ARBs, beta blockers, diuretics, MRAs, and SGLT2 inhibitors are being re-evaluated within more finely stratified treatment pathways, while combination strategies and sequencing considerations gain prominence.

Concurrently, diagnostic refinements and a deeper understanding of phenotype heterogeneity have sharpened focus on preserved versus reduced ejection fraction subtypes, and on acute as distinct from chronic management. These clinical delineations affect therapeutic selection, monitoring intensity, and expected outcomes. Mode-of-administration preferences are also shifting, as oral chronic regimens interact with intermittent or acute intravenous interventions tied to hospitalization patterns and home-based care expansion.

Operationally, distribution and access channels show parallel transformation. Offline channels anchored in hospital and retail pharmacies remain essential for acute care and specialty dispensing, while online fulfillment and telehealth-enabled prescribing are gaining traction for chronic medication continuity. End-user dynamics-clinics, home care settings, and hospitals-are adapting to new protocols for initiation, titration, and monitoring, reshaping how evidence translates into practice. The cumulative effect is a landscape where therapeutic choice, care setting, and access mechanisms co-evolve rapidly, demanding coordinated strategies across clinical, commercial, and policy domains.

Comprehensive appraisal of recent tariff-driven supply chain effects and their operational consequences for procurement, distribution, and therapeutic access frameworks

Recent tariff developments in the United States have introduced layered implications for manufacturers, distributors, and downstream care providers operating in the heart failure therapeutics space. Tariff changes influence cost structures across the supply chain, affecting the landed cost of active pharmaceutical ingredients, finished dose formulations, and device-adjacent products used in monitoring and administration. These pressures can alter contracting dynamics with hospital systems and pharmacy networks and may prompt re-evaluation of procurement strategies for both public and private payers.

The operational ripple effects extend to channel economics. Hospital pharmacy procurement practices, retail pharmacy stocking decisions, and online distribution agreements are sensitive to input-cost variability created by tariff adjustments. In response, manufacturers may pursue localized sourcing, alternative supplier partnerships, or renegotiated distribution terms to preserve margin and ensure uninterrupted patient access. Similarly, providers under value-based payment arrangements might reassess formularies and therapeutic pathways to manage total cost of care while maintaining clinical standards.

Clinicians and health system leaders will need to balance short-term operational adjustments with long-term resilience measures. This entails closer coordination among supply chain, pharmacy, and clinical leadership, increased scenario planning for potential supply disruptions, and strategic dialogue with payers to preserve access to guideline-recommended therapies. Ultimately, tariff-induced cost pressures act as a catalyst for more integrated procurement and therapeutic stewardship practices across the delivery ecosystem.

Multidimensional segmentation insights that reconcile drug class, phenotype distinctions, administration routes, care settings, and distribution architectures to inform targeted strategies

Segmentation provides the analytical scaffolding needed to translate therapeutic nuance into actionable strategy. When viewed through the lens of drug class differentiation, therapeutic choice varies markedly: ACE inhibitors and ARBs remain foundational for neurohormonal modulation, beta blockers address sympathetic overactivity, diuretics manage fluid balance in symptomatic patients, MRAs contribute to mineralocorticoid antagonism, and SGLT2 inhibitors offer metabolic and renal-cardiac benefits that cross traditional class boundaries. These class-level distinctions directly shape clinical pathways and commercial positioning.

Disaggregating by heart failure type further refines decision-making. Preserved ejection fraction and reduced ejection fraction represent biologically and operationally distinct domains; within each, acute episodes necessitate different initiation, titration, and monitoring strategies compared with chronic maintenance care. Mode of administration introduces an orthogonal axis of differentiation: intravenous therapy dominates the acute, inpatient context, while oral regimens support chronic outpatient management and enable continuity across clinic and home care settings.

End-user segmentation-clinics, home care settings, and hospitals-captures the practical realities of where therapies are initiated and maintained, influencing patient support programs, adherence interventions, and monitoring infrastructure. Distribution channel nuances between offline and online channels, with offline further split into hospital and retail pharmacies, affect time-to-treatment, inventory management, and patient convenience. Together, these intersecting segmentation axes provide a multidimensional view that supports targeted clinical protocols, differentiated commercial strategies, and operational investments in logistics and patient support.

Regional dynamics and health system characteristics that shape therapeutic adoption, reimbursement pathways, and care delivery variations across global markets

Regional dynamics exert a powerful influence on how therapies are adopted, reimbursed, and delivered across the global heart failure landscape. In the Americas, payer structures, integrated delivery networks, and a high concentration of specialist centers shape rapid protocol adoption and create pathways for specialty distribution and hospital-led therapeutics initiation. The breadth of private and public payer models also affects reimbursement negotiations and formulary placements, with implications for how therapeutic value is demonstrated.

In Europe, Middle East & Africa, heterogeneity in regulatory frameworks, funding mechanisms, and clinical infrastructure leads to variable uptake patterns. National health systems and regional procurement bodies often prioritize cost-effectiveness and therapeutic outcomes, which drives emphasis on real-world evidence generation and outcomes-based contracting. Differences in diagnostic capacity and access to specialty care can alter the balance between clinic-based initiation and hospital-centered management.

Asia-Pacific presents both large urban centers with advanced tertiary care and vast regions where access is constrained by logistics and infrastructure. This diversity influences the adoption of oral chronic regimens versus reliance on acute inpatient interventions, and it elevates the role of digital health and telemedicine in bridging care gaps. Across all regions, local regulatory nuance, supply-chain robustness, and payer expectations will determine how therapeutic innovations translate into measurable clinical impact.

Strategic corporate priorities and operational playbooks that integrate scientific differentiation, evidence generation, and distribution partnerships to support therapeutic adoption

Company strategies are increasingly defined by how effectively they align scientific differentiation with operational execution across the care continuum. Leading developers and commercial organizations are concentrating R&D, evidence generation, and lifecycle management around compounds and combinations that address unmet needs within preserved and reduced ejection fraction populations. Strategic priorities include demonstrating benefit in hard clinical outcomes, elucidating safety profiles across comorbid populations, and generating pragmatic evidence that supports adoption in routine practice.

On the commercial front, firms are optimizing launch sequencing and channel partnerships to manage the transition between inpatient initiation and outpatient maintenance. Collaboration with hospital systems, specialty pharmacies, and home care providers helps secure pathways for initiation, ensures continuity during post-discharge transitions, and supports adherence programs. Investments in real-world evidence platforms and patient monitoring technologies strengthen value propositions in negotiations with payers and integrated delivery networks.

Operationally, companies are also refining supply chain strategies to mitigate tariff and sourcing risks, enhancing forecasting models tied to clinical utilization patterns, and developing tailored pricing approaches for diverse regional reimbursement landscapes. Partnerships with digital health providers and diagnostics companies are increasingly common, aimed at connecting therapeutic interventions with monitoring and adherence solutions that improve outcomes and support long-term product differentiation.

Practical, prioritized actions for developers, payers, and providers to enhance access, evidence alignment, and supply resilience across clinical and commercial pathways

Industry leaders can take concrete steps to strengthen therapeutic access, clinical outcomes, and commercial resilience in heart failure care. First, align clinical development and post-approval evidence programs with the practical endpoints that matter to payers and health systems, such as hospitalization avoidance and functional status, while ensuring trials capture heterogeneous patient phenotypes relevant to preserved and reduced ejection fraction populations. Second, design launch and commercialization plans that bridge inpatient and outpatient settings, coordinating with hospital pharmacy teams, clinic networks, and home care providers to create clear initiation and handoff protocols.

Additionally, prioritize procurement resilience by diversifying supplier networks and exploring near-shoring options for critical inputs to reduce exposure to tariff volatility. Invest in digital and remote-monitoring tools that support adherence and early detection of decompensation, thereby enhancing clinical value and reducing downstream costs. Engage proactively with payers to develop outcome-based contracting mechanisms that align reimbursement with real-world therapeutic performance.

Finally, strengthen regional strategies by tailoring evidence generation and pricing approaches to local regulatory and reimbursement contexts. Build cross-functional teams that integrate clinical, regulatory, reimbursement, and supply chain expertise to execute complex market entry and lifecycle initiatives. These actions will help leaders convert therapeutic promise into sustained clinical and commercial impact while preserving access for patients across diverse care settings.

Robust mixed-methods research design combining frontline clinician input, targeted literature synthesis, and scenario analysis to ensure actionable and defensible insights

This research employs a mixed-methods approach designed to produce rigorous, actionable insights that bridge clinical nuance and commercial realities. Primary qualitative inputs include structured interviews with practicing cardiologists, heart failure nurses, pharmacy directors, and procurement leaders across hospital systems, clinics, and home care providers to capture firsthand perspectives on therapeutic choice, initiation pathways, and adherence challenges. These frontline insights are complemented by secondary research drawing on peer-reviewed clinical literature, regulatory guidance, and publicly available health system reports to contextualize clinical efficacy, safety, and guideline evolution.

Analytical methods include cross-sectional synthesis of therapeutic classes and care pathways, phenotype-specific clinical mapping for preserved and reduced ejection fraction populations, and scenario analysis to evaluate operational responses to supply-chain variables such as tariff changes. Mode-of-administration and distribution channel dynamics are assessed through case studies and supply-chain mapping exercises that highlight constraints and enablers across hospital pharmacies, retail pharmacies, and online fulfillment channels. Regional analysis integrates regulatory and reimbursement considerations across the Americas, Europe, Middle East & Africa, and Asia-Pacific to identify practical implications for adoption.

Throughout, findings have been triangulated across sources to ensure internal consistency and practical relevance. Limitations are acknowledged where public data are sparse or where rapidly evolving clinical evidence may alter therapeutic positioning, and recommendations emphasize adaptable strategies that can be updated as new clinical and operational data emerge.

Consolidated synthesis of clinical, operational, and regional themes underscoring pragmatic pathways to convert therapeutic advances into sustained patient benefit

In summary, the heart failure therapeutics landscape is characterized by substantive clinical evolution and operational complexity. Therapeutic differentiation now extends beyond traditional hemodynamic targets to include agents that deliver renal and metabolic benefits, necessitating more nuanced clinical decision pathways that account for phenotype, acuity, and comorbidity. These scientific advances intersect with shifting care delivery models, where clinics, hospitals, and home care settings each play distinct roles in initiation, titration, and long-term management.

At the same time, distribution and procurement dynamics-shaped by offline hospital and retail pharmacy practices as well as growing online fulfillment-require coordinated strategies to maintain access and ensure continuity of care. Tariff and supply-chain pressures underscore the need for diversified sourcing and tighter alignment between clinical, procurement, and reimbursement stakeholders. Regional variation across the Americas, Europe, Middle East & Africa, and Asia-Pacific further highlights the importance of locally tailored evidence and pricing strategies.

Ultimately, stakeholders who integrate clinical differentiation with operational rigor-aligning evidence generation, supply resilience, and payer engagement-will be best positioned to translate therapeutic advances into measurable improvements in patient outcomes. The path forward emphasizes pragmatism: targeted investments in evidence, partnerships across care settings, and proactive supply-chain management will convert potential into sustained clinical benefit.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Heart Failure Therapeutics Market, by Drug Class

  • 8.1. Ace Inhibitors
  • 8.2. Arbs
  • 8.3. Beta Blockers
  • 8.4. Diuretics
  • 8.5. Mras
  • 8.6. SGLT2 Inhibitors

9. Heart Failure Therapeutics Market, by Heart Failure Type

  • 9.1. Preserved Ejection Fraction
    • 9.1.1. Acute
    • 9.1.2. Chronic
  • 9.2. Reduced Ejection Fraction
    • 9.2.1. Acute
    • 9.2.2. Chronic

10. Heart Failure Therapeutics Market, by Mode Of Administration

  • 10.1. Intravenous
  • 10.2. Oral

11. Heart Failure Therapeutics Market, by End User

  • 11.1. Clinics
  • 11.2. Home Care Settings
  • 11.3. Hospitals

12. Heart Failure Therapeutics Market, by Distribution Channel

  • 12.1. Offline
    • 12.1.1. Hospital Pharmacies
    • 12.1.2. Retail Pharmacies
  • 12.2. Online

13. Heart Failure Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Heart Failure Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Heart Failure Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Heart Failure Therapeutics Market

17. China Heart Failure Therapeutics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Abiomed, Inc.
  • 18.7. Amgen Inc.
  • 18.8. AstraZeneca PLC
  • 18.9. Bayer AG
  • 18.10. Boehringer Ingelheim International GmbH
  • 18.11. Boston Scientific Corporation
  • 18.12. Bristol-Myers Squibb Company
  • 18.13. Cytokinetics, Inc.
  • 18.14. Edwards Lifesciences Corporation
  • 18.15. Eli Lilly and Company
  • 18.16. GlaxoSmithKline plc
  • 18.17. Johnson & Johnson
  • 18.18. Les Laboratoires Servier
  • 18.19. Medtronic plc
  • 18.20. Merck & Co., Inc.
  • 18.21. Novartis AG
  • 18.22. Pfizer Inc.
  • 18.23. Sanofi S.A.
  • 18.24. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HEART FAILURE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HEART FAILURE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ARBS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ARBS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ARBS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DIURETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DIURETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DIURETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MRAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MRAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MRAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY SGLT2 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY SGLT2 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY SGLT2 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACUTE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACUTE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACUTE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CHRONIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CHRONIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CHRONIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACUTE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACUTE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACUTE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CHRONIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CHRONIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CHRONIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 156. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 158. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 160. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 161. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 162. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 183. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 185. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 187. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 188. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 189. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 192. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 194. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 196. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 197. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 198. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)